Molecular Mechanisms of Stem Cell Engraftment
干细胞移植的分子机制
基本信息
- 批准号:8266443
- 负责人:
- 金额:$ 13.31万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-08-01 至 2015-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdhesionsAdultAffectAmericanAnoikisAreaAtomic Force MicroscopyAttentionBindingBioluminescenceCardiacCardiovascular DiseasesCause of DeathCell AdhesionCell DeathCell ProliferationCell SurvivalCell TherapyCell TransplantationCell physiologyCell surfaceCell-Matrix JunctionCellsChronic DiseaseClinicalClinical ResearchCoronary ArteriosclerosisCountryDevelopmentDiabetes MellitusDiagnosisDiseaseEchocardiographyEngraftmentEnvironmentExtracellular MatrixExtracellular Matrix ProteinsFailureGoalsGrantHeart failureHypertensionHypoxiaImmunohistochemistryInfarctionIntegrinsLeadLentivirus VectorLinkMediatingMolecularMyocardialMyocardial InfarctionMyocardial IschemiaMyocardial tissueMyocardiumNatural regenerationOperative Surgical ProceduresPhysiologicalProcessProteinsRoleSmooth MuscleStem cell transplantStem cellsSubfamily lentivirinaeTestingTherapeuticTissuesTransplantationUp-RegulationWorkWound Healingabstractingcell behaviorcell typeextracellularfunctional outcomesgenetic manipulationgenetically modified cellsheart functionimprovedin vivoinsightmigrationmouse modeloverexpressionpressurepreventpublic health relevancestem cell therapytherapy designtherapy developmenttissue regeneration
项目摘要
DESCRIPTION (provided by applicant): Heart failure is the leading cause of death in Western countries. It has been estimated that approximately 80 million American adults (1 in 3) have one or more forms of cardiovascular disease (CVD). Long-term survival after diagnosis remains poor despite recent improvements in pharmacological and surgical therapy, and development of new forms of treatment is urgently needed. Clinical studies have suggested the potential use of cell-based therapy in the treatment of CVD. However, current clinical results are inconsistent and demonstrated modest benefits. One leading issue that requires experimental attention is poor survival of injected cells. Elucidation of the mechanisms involved in stem cell death and development of new ways to prevent it upon transplantation is essential to maximize the cardioprotective and therapeutic potential of any stem cell type. Our long-term goal is to define new ways to improve stem cell retention and engraftment in the myocardium after transplantation, what can lead to increased myocardium regeneration. One of the first steps that occur after transplantation involves cell adhesion to the tissue extracellular matrix. This interaction is mediated by proteins localized on the cell surface known as integrins. In this proposal, we will test if specific integrins can enhance cardiac stem cell attachment to the myocardium extracellular matrix when overexpressed, and improve myocardium regeneration and function. Our proposed aims will advance understanding of stem cell engraftment in ischemic myocardium and allow direct determination of the link between enhanced engraftment and functional outcome of cell therapy. Insights developed from this grant could provide a significant translational advance in the new area of cell-based therapy.
PUBLIC HEALTH RELEVANCE: Heart failure is the leading cause of death from cardiovascular diseases and is the end result of a number of chronic illnesses, including hypertension, diabetes, and coronary artery disease. Long-term survival after diagnosis remains poor despite recent improvements in pharmacological and surgical therapy, and development of new forms of treatment, such as stem cell therapy, is urgently needed. (End of Abstract)
描述(由申请人提供):心力衰竭是西方国家的主要死亡原因。据估计,大约有8000万美国成年人(三分之一)患有一种或多种心血管疾病(CVD)。尽管最近在药物和手术治疗方面取得了进展,但诊断后的长期生存率仍然很低,迫切需要开发新的治疗方法。临床研究表明,细胞疗法在心血管疾病的治疗中具有潜在的应用价值。然而,目前的临床结果不一致,并且显示出适度的益处。需要引起实验注意的一个主要问题是注射细胞的存活率差。阐明干细胞死亡的机制和开发新的方法来预防移植后的死亡,对于最大限度地发挥任何干细胞类型的心脏保护和治疗潜力至关重要。我们的长期目标是确定新的方法来改善移植后心肌中的干细胞保留和植入,从而增加心肌再生。移植后发生的第一步是细胞与组织细胞外基质的粘附。这种相互作用是由位于细胞表面的蛋白质介导的,称为整合素。在本研究中,我们将测试特异性整合素在过度表达时是否能增强心脏干细胞对心肌细胞外基质的附着,并改善心肌的再生和功能。我们提出的目标将促进对缺血心肌干细胞植入的理解,并允许直接确定增强植入与细胞治疗功能结果之间的联系。从这项资助中获得的见解可以为细胞治疗的新领域提供重大的转化进展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CLAUDIA OLIVEIRA RODRIGUES其他文献
CLAUDIA OLIVEIRA RODRIGUES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CLAUDIA OLIVEIRA RODRIGUES', 18)}}的其他基金
A Novel Role for cMyc in Vascular Homeostasis
cMyc 在血管稳态中的新作用
- 批准号:
10159716 - 财政年份:2020
- 资助金额:
$ 13.31万 - 项目类别:
A Novel Role for cMyc in Vascular Homeostasis
cMyc 在血管稳态中的新作用
- 批准号:
10092385 - 财政年份:2020
- 资助金额:
$ 13.31万 - 项目类别:
A Novel Role for cMyc in Vascular Homeostasis
cMyc 在血管稳态中的新作用
- 批准号:
10449636 - 财政年份:2017
- 资助金额:
$ 13.31万 - 项目类别:
A Novel Role for cMyc in Vascular Homeostasis
cMyc 在血管稳态中的新作用
- 批准号:
9383491 - 财政年份:2017
- 资助金额:
$ 13.31万 - 项目类别:
相似海外基金
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y004841/1 - 财政年份:2024
- 资助金额:
$ 13.31万 - 项目类别:
Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
- 批准号:
BB/Y001427/1 - 财政年份:2024
- 资助金额:
$ 13.31万 - 项目类别:
Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y005414/1 - 财政年份:2024
- 资助金额:
$ 13.31万 - 项目类别:
Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
- 批准号:
10669829 - 财政年份:2023
- 资助金额:
$ 13.31万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10587090 - 财政年份:2023
- 资助金额:
$ 13.31万 - 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
- 批准号:
10821599 - 财政年份:2023
- 资助金额:
$ 13.31万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10841832 - 财政年份:2023
- 资助金额:
$ 13.31万 - 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
- 批准号:
10532480 - 财政年份:2022
- 资助金额:
$ 13.31万 - 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
- 批准号:
10741261 - 财政年份:2022
- 资助金额:
$ 13.31万 - 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
- 批准号:
10674894 - 财政年份:2022
- 资助金额:
$ 13.31万 - 项目类别: